DECISION DIAGNOSTICS DECN overview

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Decision Diagnostics Corp. (OTC: DECN) between March 3, 2020 and December 17, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Decision Diagnostics investors under the federal securities laws. To join the Decision Diagnostics class action, go to http://www.rosenlegal.com/cases-register-2009.html or call Phillip Kim, Esq....

The company and its CEO thank supporters and remain fully committed; company will also provide a series of GenViro! test results it has amassed demonstrating the technology's promise LOS ANGELES, CA / ACCESSWIRE / December 21, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co , a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., as well as the...

LOS ANGELES, CA / ACCESSWIRE / December 18, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co , a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., as well as the designer and manufacturer of the GenViro! Covid-19 Swift Kit testing kits, hereby confirms two recent legal filings by separate agencies of the Federal government regarding DECN and its CEO...

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Decision Diagnostics Corp. (OTC: DECN) resulting from allegations that Decision may have issued materially misleading business information to the investing public. This spring, Decision’s CEO Keith Berman claimed to have a test that could test for the novel coronavirus with a finger prick and provide results in less than a minute. On December 17, 2020, the...

As clinical testing in Pennsylvania nears completion for pro and point of care GenViro! kits, Korean partner initiates PCR validation testing to augment testing of their saliva donors and the XPRIZE samples DECN plans 150 patient donor study to complete its at-home testing kit EUA LOS ANGELES, CA / ACCESSWIRE / December 16, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co , a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate...

WITH THIS DEAL THE TOTAL NUMBER OF COUNTRIES COVERED BY DECN INTERNATIONAL AGREEMENTS NOW APPROACHES 50 WITH MORE ANTICIPATED LOS ANGELES, CA / ACCESSWIRE / December 10, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co , a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., today announced it has signed an exclusive distribution agreement for its...

Company Continues to Pursue Global Distribution Agreements During the "Home Stretch" in U.S. Based FDA Level Testing LOS ANGELES, CA / ACCESSWIRE / December 1, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co , a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., today announced it has signed an agreement for the sale of its Genviro! and Genviro! Pro...

Data using XPRIZE supplied contrived fluid samples provides results comparable to those seen in the FDA lab testing of donor saliva, as DECN competes for the $5 million prize and GLOBAL validation LOS ANGELES, CA / ACCESSWIRE / November 23, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co , a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters along with its subsidiary Pharma Tech Solutions, Inc., the...